T
48.92
-2.45 (-4.77%)
| Previous Close | 51.37 |
| Open | 51.33 |
| Volume | 688,400 |
| Avg. Volume (3M) | 670,700 |
| Market Cap | 2,014,828,800 |
| Price / Sales | 10.63 |
| Price / Book | 9.49 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | -63.16% |
| Operating Margin (TTM) | -36.77% |
| Diluted EPS (TTM) | -3.07 |
| Quarterly Revenue Growth (YOY) | 407.90% |
| Total Debt/Equity (MRQ) | 32.27% |
| Current Ratio (MRQ) | 4.43 |
| Operating Cash Flow (TTM) | -83.03 M |
| Levered Free Cash Flow (TTM) | -50.48 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -54.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tarsus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.30 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 8.28% |
| % Held by Institutions | 103.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 78.00 (Guggenheim, 59.44%) | Buy |
| Median | 72.00 (47.18%) | |
| Low | 58.00 (Jefferies, 18.56%) | Buy |
| Average | 68.20 (39.41%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 43.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 06 Mar 2025 | 58.00 (18.56%) | Buy | 43.57 |
| Barclays | 26 Feb 2025 | 60.00 (22.65%) | Buy | 42.56 |
| 27 Jan 2025 | 62.00 (26.74%) | Buy | 51.45 | |
| Guggenheim | 26 Feb 2025 | 78.00 (59.44%) | Buy | 42.56 |
| HC Wainwright & Co. | 26 Feb 2025 | 73.00 (49.22%) | Buy | 42.56 |
| Oppenheimer | 22 Jan 2025 | 72.00 (47.18%) | Buy | 48.11 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AZAMIAN BOBAK R. | - | 51.14 | -14,534 | -740,092 |
| FARROW JEFFREY S | - | 49.91 | -1,186 | -59,193 |
| MOTTIWALA AZIZ | - | 49.91 | -3,365 | -167,947 |
| NEERVANNAN SESHADRI | - | 49.91 | -2,435 | -121,531 |
| WAHL BRYAN | - | 49.91 | -3,084 | -153,922 |
| WHITFIELD DIANNE C. | - | 49.91 | -2,137 | -106,658 |
| Aggregate Net Quantity | -26,741 | |||
| Aggregate Net Value ($) | -1,349,343 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 50.26 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AZAMIAN BOBAK R. | Officer | 24 Mar 2025 | Automatic sell (-) | 6,000 | 52.36 | 314,160 |
| FARROW JEFFREY S | Officer | 20 Mar 2025 | Sell (-) | 1,186 | 49.91 | 59,193 |
| AZAMIAN BOBAK R. | Officer | 20 Mar 2025 | Sell (-) | 8,534 | 49.91 | 425,932 |
| WHITFIELD DIANNE C. | Officer | 20 Mar 2025 | Sell (-) | 2,137 | 49.91 | 106,658 |
| WAHL BRYAN | Officer | 20 Mar 2025 | Sell (-) | 3,084 | 49.91 | 153,922 |
| NEERVANNAN SESHADRI | Officer | 20 Mar 2025 | Sell (-) | 2,435 | 49.91 | 121,531 |
| MOTTIWALA AZIZ | Officer | 20 Mar 2025 | Sell (-) | 3,365 | 49.91 | 167,947 |
| Date | Type | Details |
|---|---|---|
| 12 Mar 2025 | Announcement | Tarsus Announces Proposed $100.0 Million Public Offering |
| 06 Mar 2025 | Announcement | Tarsus to Participate in Upcoming Investor Conference |
| 25 Feb 2025 | Announcement | Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements |
| 20 Feb 2025 | Announcement | Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 |
| 30 Jan 2025 | Announcement | Tarsus to Participate in Upcoming Investor Conferences |
| 13 Jan 2025 | Announcement | Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |